Analgesic Effect of Xenon in Rat Model of Inflammatory Pain

Кукушкин, М. Л.; Igonʼkina, S. I.; Potapov, S. V.; Потапов, А. В.

doi:10.1007/s10517-017-3637-x

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Koziakova et al (2019) demonstrated that the neuroprotective effect of xenon may be mediated by inhibition of the N -methyl-d-aspartate receptor at the glycine site. Kukushkin et al (2017) demonstrated that in simulated models of two kinds of physiological pain (formalin-induced acute pain and tonic pain), the TWL of pain behavior in rats was relieved after 15 min after inhalation of 50/50% xenon/oxygen for 30 min. The analgesic effect of PWMT was stable within 60 min ( Kukushkin et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

“… Kukushkin et al (2017) demonstrated that in simulated models of two kinds of physiological pain (formalin-induced acute pain and tonic pain), the TWL of pain behavior in rats was relieved after 15 min after inhalation of 50/50% xenon/oxygen for 30 min. The analgesic effect of PWMT was stable within 60 min ( Kukushkin et al, 2017 ). Where xenon plays a major role in this sensitization is the long-lasting depolarization of glutamate and neurokinin exerted on nociceptive dorsal horn neurons ( Kukushkin & Igonkina, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Xenon ameliorates chronic post-surgical pain by regulating mitophagy in microglia and rats mediated by PINK1/Parkin pathway

Lv,

Huang,

Zhang

et al. 2024

PeerJ

View full text Add to dashboard Cite

Background Chronic post-surgical pain (CPSP) is one of the important causes of poor postoperative outcomes, the activation of microglia in the spinal cord is closely related to the generation, transmission and maintenance of CPSP. Xenon (Xe), an anesthetic gas, has been reported to be able to significantly reduce intraoperative analgesia and postoperative pain sensation at low doses. However, the mechanism of the regulatory effect of xenon on activated microglia after CPSP remains unclear. Methods In this study, CPSP model rats were treated with 50% Xe inhalation for 1 h following skin/muscle incision and retraction (SMIR), once a day for 5 consecutive days, and then the painbehavioraltests (pain behavior indexes paw withdrawal mechanical threshold, PWMT and thermal withdrawal latency, TWL), microglial activation, oxidative stress-related indexes (malondialdehyde, MDA; superoxide dismutase, SOD; hydrogen peroxide, H2O2; and catalase, CAT), mitophagy and PINK1/Parkin pathway were examined. Results The present results showed that a single dose of Xe treatment in SMIR rat model could significantly improve PWMT and TWL in the short-term at a single treatment and long-term at multiple treatments. Xe treatment inhibited microglia activation and oxidative stress in the spinal dorsal horn of SMIR rats, as indicated by the decrease of Iba1 and MDA/H2O2 levels and the increase of SOD/CAT levels. Compared with the control group, Xe further increased the CPSP promoted Mito-Tracker (a mitochondrial marker) and LC3 (an autophagy marker) co-localization positive spots and PINK1/Parkin/ATG5/BECN1 (autophagy-related proteins) protein expression levels, and inhibited the Mito-SOX (a mitochondrial reactive oxygen species marker) positive signal, indicating that Xe promoted microglia mitophagy and inhibited oxidative stress in CPSP. Mechanistically, we verified that Xe promoted PINK1/Parkin signaling pathway activation. Conclusion Xe plays a role in ameliorating chronic post-surgical pain by regulating the PINK1/Parkin pathway mediated microglial mitophagy and provide new ideas and targets for the prevention and treatment of CPSP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Xenon ameliorates chronic post-surgical pain by regulating mitophagy in microglia and rats mediated by PINK1/Parkin pathway

Lv,

Huang,

Zhang

et al. 2024

PeerJ

View full text Add to dashboard Cite

show abstract

The possibilities of using xenon therapy in patients with severe cancer pain

et al. 2020

View full text Add to dashboard Cite

In accordance with the clinical recommendations of the World Health Organization and the Ministry of Health of the Russian Federation, the main analgesics for the treatment of chronic cancer pain are non-opioid and opioid analgesics, given stepwise in combination with co-analgesics and adjuvant drugs. As a rule, this stepwise scheme of painkilling is effective in most cases. However, 20-30% of patients cannot achieve an acceptable level of pain relief despite the use of these analgesics in combination. Is there another way to help such patients? Interventional methods of analgesia are an option, yet not all patients agree to invasive methods due to the possible side effects and unavailability of these methods. In these cases other mechanisms of analgesia are required, such as NMDA receptor antagonists, which reduce opioid tolerance and hyperalgesia. Still not all the drugs of this group can be applied in our practice. Analgesic properties of nitrous oxide can only be found in high anesthetic doses. Another option is metadon, but it is forbidden and cannot be used in our country. Still one more option is ketamine, which has severe side effects. In our clinical practice we decided to use xenon, which has NMDA inhibition effects. Its analgesic effect and safety have been confirmed in numerous studies. This publication aims to demonstrate a successful clinical case when we used xenon and oxygen inhalations course for the treatment of a severe cancer pain with a patient who had been taking morphine by mouth.

show abstract

Analgesic Effect of Xenon in Rat Model of Inflammatory Pain

Cited by 2 publications

References 6 publications

Xenon ameliorates chronic post-surgical pain by regulating mitophagy in microglia and rats mediated by PINK1/Parkin pathway

Xenon ameliorates chronic post-surgical pain by regulating mitophagy in microglia and rats mediated by PINK1/Parkin pathway

The possibilities of using xenon therapy in patients with severe cancer pain

Contact Info

Product

Resources

About